0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Protein > Spike protein > SPN-C52H3

SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (MALS verified)

Order Now

  • Synonym
    Spike,S protein,Spike glycoprotein,S glycoprotein
  • Source
    SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (SPN-C52H3) is expressed from human 293 cells (HEK293). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus

    The protein has a calculated MW of 138.0 kDa. The protein migrates as 170-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Spike protein SDS-PAGE

SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Spike protein MALS images

The purity of SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (Cat. No. SPN-C52H3) is more than 90% and the molecular weight of this protein is around 520-620 kDa verified by SEC-MALS.

Bioactivity-ELISA
 Spike protein ELISA

Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (Cat. No. SPN-C52H3) with a linear range of 0.2-5 ng/mL (QC tested).

 Spike protein ELISA

Immobilized Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (Cat. No. SPN-C52H3) with a linear range of 0.2-2 ng/mL (Routinely tested).

  • Background
    It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
  • Clinical and Translational Updates
  • Purchaser Notification
    Important Licensing Information: This product may be covered by Limited Use Label License(s). By use of this product, you accept the terms and conditions of all applicable Limited Use Label License(s).
  • Limited Use Label License No. 18: Engineered Coronavirus Spike Proteins
    This product and its use is the subject of U.S. Provisional Patent Application No. 63/032,502 and sold under a license from The University of Texas at Austin. Rights to use this product are limited to research and clinical diagnostics, and expressly exclude the right to use in human therapeutics, vaccines, and any use involving the administration of this product to humans.

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €450.00

Price(EUR) : €3110.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje